BR112021010241A2 - Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso - Google Patents

Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso

Info

Publication number
BR112021010241A2
BR112021010241A2 BR112021010241A BR112021010241A BR112021010241A2 BR 112021010241 A2 BR112021010241 A2 BR 112021010241A2 BR 112021010241 A BR112021010241 A BR 112021010241A BR 112021010241 A BR112021010241 A BR 112021010241A BR 112021010241 A2 BR112021010241 A2 BR 112021010241A2
Authority
BR
Brazil
Prior art keywords
expression
methods
immunomodulatory proteins
multigene construct
proteins
Prior art date
Application number
BR112021010241A
Other languages
English (en)
Inventor
A Canton David
Original Assignee
Oncosec Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Inc filed Critical Oncosec Medical Inc
Publication of BR112021010241A2 publication Critical patent/BR112021010241A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Electrotherapy Devices (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

construto multigene para expressão de proteínas imunomodulatórias e métodos de uso. a presente invenção refere-se a construtos de vetor de expressão que codificam as proteínas il-12 p35 e il-12 p40, em que cada proteína ou componente dos mesmos pode ser expresso utilizando promotores apropriados e/ou modificadores de tradução. também são fornecidos métodos de uso para os vetores de expressão.
BR112021010241A 2018-12-11 2019-12-11 Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso BR112021010241A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862778027P 2018-12-11 2018-12-11
PCT/US2019/065639 WO2020123602A1 (en) 2018-12-11 2019-12-11 Multigene construct for immune-modulatory protein expression and methods of use

Publications (1)

Publication Number Publication Date
BR112021010241A2 true BR112021010241A2 (pt) 2021-11-03

Family

ID=71076619

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021010241A BR112021010241A2 (pt) 2018-12-11 2019-12-11 Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso

Country Status (12)

Country Link
US (1) US20220040328A1 (pt)
EP (1) EP3894563A4 (pt)
JP (2) JP7178139B2 (pt)
KR (1) KR20210091323A (pt)
CN (1) CN113302304A (pt)
AU (1) AU2019398202A1 (pt)
BR (1) BR112021010241A2 (pt)
CA (1) CA3122395A1 (pt)
IL (1) IL283830A (pt)
MX (1) MX2021006922A (pt)
SG (1) SG11202105472QA (pt)
WO (1) WO2020123602A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240024328A (ko) * 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
CN111093689A (zh) 2017-07-03 2020-05-01 转矩医疗股份有限公司 免疫刺激融合分子及其用途
WO2022081776A1 (en) * 2020-10-13 2022-04-21 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9273300B2 (en) * 2007-02-07 2016-03-01 Strike Bio, Inc Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
US9683237B2 (en) 2014-04-25 2017-06-20 Strike Bio, Inc. Multiple targeted RNAI for the treatment of cancers
AU2016369608B2 (en) 2015-12-18 2023-02-02 Jean Campbell Plasmid constructs for heterologous protein expression and methods of use
CN109561691A (zh) * 2016-06-07 2019-04-02 太平洋心肺血研究所 用于治疗癌症的组合物和方法
US20200123566A1 (en) * 2017-06-13 2020-04-23 Oncosec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
TW202039537A (zh) * 2018-11-27 2020-11-01 美商昂科賽克醫療公司 用於治療癌症之質體建構體和使用方法

Also Published As

Publication number Publication date
KR20210091323A (ko) 2021-07-21
US20220040328A1 (en) 2022-02-10
JP7178139B2 (ja) 2022-11-25
AU2019398202A1 (en) 2021-08-05
JP2022513201A (ja) 2022-02-07
MX2021006922A (es) 2021-09-30
EP3894563A4 (en) 2022-10-12
CA3122395A1 (en) 2020-06-18
JP2023017930A (ja) 2023-02-07
SG11202105472QA (en) 2021-06-29
CN113302304A (zh) 2021-08-24
WO2020123602A1 (en) 2020-06-18
IL283830A (en) 2021-07-29
EP3894563A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
BR112018070260A2 (pt) receptores quiméricos e métodos de uso dos mesmos
CY1123609T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ΄ αυτων
BR112021010241A2 (pt) Construto multigene para expressão de proteínas imunomodulatórias e métodos de uso
CL2023000896A1 (es) Receptores quiméricos de dll3 y métodos para su uso
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
BR112019005964A2 (pt) proteínas de fusão imunomoduladoras
EA201691111A1 (ru) Химерные белки фактора viii и их применение
MY197854A (en) Antibodies against signal-regulatory protein alpha and methods of use
BR112018074325A2 (pt) anticorpo para ligação a receptor de interleucina 4
BR112018070187A8 (pt) receptores quiméricos para flt3 e seus métodos de uso
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
EA201890729A1 (ru) Настраиваемые варианты доменов суперсемейства иммуноглобулинов и терапия сконструированными клетками
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
BR112018008840A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112021016272A2 (pt) Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos
EA202090563A1 (ru) Анти-pacap антитело
BR112017022076A2 (pt) fusões de mesotelina-variante iii de receptor de fator de crescimento epidérmico e métodos de uso das mesmas
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
BR112018005464A2 (pt) expressão de proteínas contendo fc
BR112021017486A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112022001688A2 (pt) Receptores de células t e métodos de uso dos mesmos
BR112021017479A2 (pt) Receptores de células t e métodos de uso dos mesmos